https://pharminent.com/oncology/oncology-intelligence-digest-october-30-2026/ 2026-10-31T00:34:05Z Pharminent en Oncology Intelligence Digest • October 30, 2026 2026-10-31T00:34:05Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-october-30-2026/ 2026-10-31T00:33:50Z Pharminent en GLP-1 Competitive Market Digest • Weekly • October 30, 2026 2026-10-31T00:33:50Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-october-30-2026/ 2026-10-30T14:20:57Z Pharminent en Strategic News Watch • October 30, 2026 2026-10-30T14:20:57Z Blog https://pharminent.com/genmabs-cancer-antibody-succeeds-in-phase-3-head-and-neck-trial/ 2026-10-30T11:46:01Z Pharminent en Genmab's cancer antibody succeeds in phase 3 head and neck trial 2026-10-30T11:46:01Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-october-29-2026/ 2026-10-30T11:07:51Z Pharminent en Rare Disease & Gene Therapy Digest • October 29, 2026 2026-10-30T11:07:51Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-october-29-2026/ 2026-10-29T14:57:35Z Pharminent en Strategic News Watch • October 29, 2026 2026-10-29T14:57:35Z Blog https://pharminent.com/lilly-beats-estimates-raises-sales-outlook-on-zepbound-and-mounjaro/ 2026-10-29T11:59:48Z Pharminent en Merck tops quarterly estimates and raises profit outlook on Keytruda 2026-10-29T11:45:45Z Blog